OakChart

Jupiter Neurosciences Inc

JUNSHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.14-0.08 (-3.60%)
2026-11-12 03:36 CET
Market cap
2.82 USD m
Revenue, TTM
0.06 USD m
Net income, TTM
-9.20 USD m
Free cash flow, TTM
-7.25 USD m
EPS diluted, TTM
-19.11
P/E
-
Compare

Price

JUNS against its 20, 50 and 200-day averages
2050200
0.0020.0040.0060.0026.2M52.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JUNSclose 2.1420-day 2.5250-day 2.77200-day 18.012.14

97.9% under the 52-week high of 103.50 on 11 Nov 2025. 52-week low 2.01 on 6 Nov 2026. Last 15 sessions, 60.2% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

JUNS
52-week range, 0% of the way up
2.01103.5

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The firm offers JOTROL, an enhanced orally administered resveratrol formulation, designed to deliver therapeutically relevant, safe levels of resveratrol. The company was founded by Christer Rosen, Alexander Rosen, Claes Wahlestedt, Marshall Hayward, and Shaun P. Brothers in January 2016 and is headquartered in Jupiter, FL.

Employees5
IPODec 03, 2024
Beta1.66
ATR, 14d0.29
Rel volume0.01
Short float2.76%
Insider own31.06%
Inst own75.64%

Snapshot

6 groups

Valuation

Index-
Market Cap2.82M
Enterprise Value3.08M
Income-9.20M
Sales0.06M
Book/sh-0.55
Cash/sh1.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPODec 03, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S47.07
P/B-
P/C1.86
P/FCF-
EV/EBITDA-
EV/Sales51.41
Quick Ratio0.62
Current Ratio0.66
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-19.11
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-18.30% -7.78%
Sales past 3/5Y- -
EPS Y/Y TTM-43.11%
Sales Y/Y TTM-
EPS Q/Q19.90%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.0.00% -

Ownership

Insider Own31.06%
Insider Trans0.00%
Inst Own75.64%
Inst Trans15.89%
ROA-239.36%
ROE-1888.70%
ROIC-
Gross Margin81.80%
Oper. Margin-15166.68%
Profit Margin-14220.12%
SMA20-15.16%
SMA50-22.63%
SMA200-88.12%
Trades-

Technical

Shs Outstand1.32M
Shs Float0.91M
Short Float2.76%
Short Ratio0.03
Short Interest0.03M
52W High103.50 -97.93%
52W Low2.01 6.47%
Volatility8.63% 10.86%
ATR (14)0.29
RSI (14)37.86
Beta1.66
Rel Volume0.01
Avg Volume881.57K
Volume8,853

Performance

Perf Week-13.01%
Perf Month-36.31%
Perf Quarter-64.33%
Perf Half Y-91.52%
Perf YTD-97.20%
Perf Year-97.85%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price1875.00
Prev Close2.22
Price2.14
Change %-3.60%

Peers

Mkt cap
TickerCompanyMkt cap
ALZNAlzamend Neuro Inc6.32M
NRSNNeuroSense Therapeutics Ltd3.38M
LRMRLarimar Therapeutics Inc283.61M
ANVSAnnovis Bio Inc36.41M
BIVIBioVie Inc13.51M
CRVOCervoMed Inc26.78M
ADXNAddex Therapeutics Ltd ADR3.02M
SILOSILO Pharma Inc2.92M
ACOGAlpha Cognition Inc187.72M
IKTInhibikase Therapeutics Inc227.44M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 104
  • Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value (GlobeNewswire) +18.18%
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -15.31%
  • Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire) +19.92%
  • Real Parkinson's Disease Hope from Jupiter Neurosciences (Exec Edge) -5.14%
  • Jupiter Neurosciences, Inc. Announces Reverse Stock Split (GlobeNewswire) -25.68%
  • Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva (IPO-Edge.com)
  • Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosen & President Alison Silva (Ipo Edge)
  • Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) (InvestorsHub)
  • Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million (GlobeNewswire)
  • Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson (GlobeNewswire)
  • Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease (GlobeNewswire)
  • D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering (ACCESSWIRE)
  • Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering (GlobeNewswire) +32.10% -12.19%
  • Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering (GlobeNewswire) -35.94%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q32025-12-03-6.000-6.000-5.0420.000.001
2025Q22025-09-03-5.250-5.250-5.0930.000.001
2025Q12025-05-28-3.750-3.750-3.4640.000.001
2024Q42025-02-26-3.750-1.500-3.4610.000.001
2024Q32024-11-27-1.500--1.3390.00--
2025Q4---5.250-5.606-0.081
2026Q1---3.750-4.387-0.231
2026Q2---3.750-4.079-0.401
2026Q3---3.750--0.601
2026Q4--14.250--10.911
2027Q1---3.750--1.171
2027Q2---5.250--1.531
2027Q3---5.250--2.011
2027Q4---5.250--2.651

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-6.000-4.500-0.000.00
2025FY--19.500-18.724-0.08
2026FY-4.500--12.13
2027FY--19.500--7.36

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q4S2026-01-171000.080.080.08
2025Q4S2025-12-031010.080.080.08
2025Q4S2025-11-031010.080.080.08
2025Q4S2025-09-031000.130.130.13
2025Q4S2025-08-031000.130.130.13
2025Q4S2025-05-281100.130.130.13
2025Q4S2025-05-201100.130.130.13
2025Q4S2025-02-261000.000.000.00
2025Q4S2025-02-141000.000.000.00
2025Q4S2025-02-131000.000.000.00
2025Q4S2025-02-121000.000.000.00
2025Q4S2025-02-111000.000.000.00
2025Q4S2025-02-101000.000.000.00
2025Q4S2025-02-091000.000.000.00

Estimate history

EPS, annual-23.701-12.872-32.675-11.309-10.838-5.528-18.724-19.1138
Period2019202020212022202320242025TTM
EPS, quarterly0.71-1.339-3.461-3.464-5.093-5.042-5.606-4.387-4.079
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000.0220.06
Period2019202020212022202320242025TTM
Sales, quarterly0000000.0220.0190.024
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1290.1290.1290.4380.4410.4410.4590.665
Period2019202020212022202320242025MRQ
Shares, quarterly0.4410.4410.4410.4410.4640.4570.4590.4840.665
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.060.020.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.000.000.00---0.00
Gross Profit0.050.020.000.00---0.00
Selling, General and Administrative Excl. Other9.868.933.093.873.674.552.982.18
Research and Development1.872.090.490.950.941.451.640.69
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.81-8.91-3.09-3.87-3.67-4.55-2.98-2.18
Interest Expense0.270.070.250.220.740.110.010.32
Unusual Expense-0.83-0.28-0.840.740.780.18-0.130.57
Net Income Before Taxes-9.20-8.64-2.44-4.78-4.96-4.20-1.65-3.05
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.20-8.64-2.44-4.78-4.96-4.20-1.65-3.05
Net Income From Continuing Operations-9.20-8.64-2.44-4.78-4.96-4.20-1.65-3.05
Net Income-9.20-8.64-2.44-4.78-4.96-4.20-1.65-3.05
EPS (Recurring)-17.54-19.15-6.87-9.67-10.06-31.70-13.57-20.61
EPS (Basic, Before Extraordinaries)-19.11-18.72-5.53-10.84-11.31-32.67-12.87-23.70
EPS (Diluted)-19.11-18.72-5.53-10.84-11.31-32.67-12.87-23.70
EBITDA-9.81-8.91-3.09-3.87-3.67-4.55-2.98-2.18
Non-Operating Income (Expense)0.050.050.060.040.230.641.210.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.532.421.841.200.751.300.500.94
Price To Sales Ratio138.461,620.53------
Gross Margin81.8080.59------
Operating Margin-15,166.68-40,873.19------
Net Margin-14,220.12-39,662.77------
Shares Outstanding0.660.460.440.440.440.130.130.13
Market Capitalization2.822.8237.01-----

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.020.020.020.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.020.010.020.000.000.000.000.00
Selling, General and Administrative Excl. Other2.761.982.832.302.261.541.460.49
Research and Development0.600.410.040.820.760.470.200.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.74-1.96-2.81-2.30-2.26-1.54-1.46-0.49
Interest Expense0.090.120.060.000.000.000.030.11
Unusual Expense-0.55-0.00-0.280.000.000.000.09-0.01
Net Income Before Taxes-2.27-2.06-2.58-2.29-2.25-1.53-1.53-0.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.27-2.06-2.58-2.29-2.25-1.53-1.53-0.59
Net Income From Continuing Operations-2.27-2.06-2.58-2.29-2.25-1.53-1.53-0.59
Net Income-2.27-2.06-2.58-2.29-2.25-1.53-1.53-0.59
EPS (Recurring)-4.77-4.39-6.04-5.04-5.09-3.46-3.31-1.35
EPS (Basic, Before Extraordinaries)-4.08-4.39-5.61-5.04-5.09-3.46-3.46-1.34
EPS (Diluted)-4.08-4.39-5.61-5.04-5.09-3.46-3.46-1.34
EBITDA-2.74-1.96-2.81-2.30-2.26-1.54-1.46-0.49
Non-Operating Income (Expense)0.010.020.010.010.010.010.060.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.490.500.461.070.460.421.010.20
Price To Sales Ratio138.46327.911,612.01-----
Gross Margin86.8876.6180.59-----
Operating Margin-11,313.45-10,524.34-12,886.70-----
Net Margin-9,380.89-11,054.89-11,814.24-----
Shares Outstanding0.660.480.460.460.460.440.440.44
Market Capitalization2.8213.6535.1460.3635.5320.1923.17-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments3.793.770.030.060.330.210.00
Short Term Receivables0.000.000.000.000.000.130.00
Inventories0.160.000.000.000.000.000.00
Other Current Assets0.870.880.000.010.120.220.00
Total Current Assets4.824.650.030.070.450.550.00
Net Property, Plant & Equipment0.020.070.120.160.210.000.00
Total Investments and Advances0.000.000.000.000.000.000.00
Long-Term Note Receivable----0.000.500.00
Intangible Assets-----0.00-
Other Assets0.721.480.000.000.000.000.00
Total Assets5.566.200.150.240.671.050.01
Short Term Debt Incl. Current Port. of LT Debt5.320.202.071.780.490.111.21
Accounts Payable0.130.280.190.190.260.250.13
Other Current Liabilities1.951.533.515.294.943.903.68
Total Current Liabilities7.402.015.777.265.684.265.02
Long Term Debt0.000.020.180.120.160.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities7.402.035.957.385.854.265.02
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-1.834.17-5.80-7.14-5.18-3.21-5.02
Total Shareholders Equity-1.834.17-5.80-7.14-5.18-3.21-5.02
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity-1.834.17-5.80-7.14-5.18-3.21-5.02
Total Liabilities & Stockholders Equity5.566.200.150.240.671.050.01
Book Value Per Share-3.999.45-13.14-16.30-40.28-24.98-39.02
Tangible Book Value Per Share-3.999.45-13.14-16.30-40.28-24.98-39.02
Full-Time Employees544-55-
Price to Book Ratio-3.89644.52-----
Return on Assets-146.94-76.83-2,488.03-1,097.63-489.15-313.34-
Return on Equity-738.83------
Return on Invested Capital--58.18-----
Quick Ratio0.632.310.000.010.080.130.00
Current Ratio0.652.310.000.010.080.130.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-9.20-8.64-2.44-4.78-4.96-4.20-1.65-3.05
Other Funds (Non Cash)2.753.131.091.952.161.680.371.81
Funds from Operations-6.45-5.52-1.35-2.83-2.80-2.52-1.28-1.24
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.800.11-2.572.351.550.781.031.09
Cash from Operating Activities-7.25-5.41-3.91-0.48-1.25-1.74-0.25-0.14
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock1.870.000.150.060.000.830.700.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.870.000.150.060.000.830.700.00
Proceedsfrom Stock Options1.860.000.150.000.000.000.700.00
Issuance or Reduction of Debt, Net5.035.43-2.220.390.980.53-0.240.11
Change in Long Term Debt5.585.58-0.150.000.000.000.000.00
Issuance of Long Term Debt5.585.580.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.150.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.009.730.000.000.500.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities6.895.437.650.450.981.860.460.11
Net Change in Cash-0.360.023.74-0.04-0.270.120.21-0.04
Free Cash Flow-7.25-5.41-3.91-0.48-1.25-1.74-0.25-0.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.522.363.790.721.882.71
Short Term Receivables0.010.000.000.000.000.00
Inventories0.140.150.160.000.000.00
Other Current Assets0.880.900.870.910.940.90
Total Current Assets2.553.414.821.632.823.61
Net Property, Plant & Equipment0.220.010.020.030.050.06
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.950.530.720.911.101.29
Total Assets3.723.955.562.583.974.96
Short Term Debt Incl. Current Port. of LT Debt1.574.865.320.190.190.20
Accounts Payable0.360.090.130.370.470.16
Other Current Liabilities1.951.781.951.961.971.53
Total Current Liabilities3.886.737.402.522.631.89
Long Term Debt0.210.000.000.000.000.01
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.086.737.402.522.631.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.37-2.78-1.830.061.343.06
Total Shareholders Equity-0.37-2.78-1.830.061.343.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-0.37-2.78-1.830.061.343.06
Total Liabilities & Stockholders Equity3.723.955.562.583.974.96
Book Value Per Share-0.55-5.75-3.990.132.896.94
Tangible Book Value Per Share-0.55-5.75-3.990.132.896.94
Full-Time Employees--5---
Price to Book Ratio-3.89-4.90-19.181,051.2126.516.59
Return on Assets-239.36-205.98-146.94-555.21-282.33-131.28
Return on Equity-1,888.70-6,529.17-738.83---
Return on Invested Capital----3,984.94-168.12-49.75
Quick Ratio0.620.480.630.651.071.91
Current Ratio0.660.510.650.651.071.91

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.27-2.06-2.58-2.29-2.25-1.53
Other Funds (Non Cash)0.140.820.601.200.720.61
Funds from Operations-2.14-1.24-1.98-1.09-1.53-0.92
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.16-0.19-0.39-0.060.71-0.14
Cash from Operating Activities-2.29-1.43-2.37-1.15-0.83-1.06
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.860.010.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.860.010.000.000.000.00
Proceedsfrom Stock Options1.860.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.410.005.430.000.000.00
Change in Long Term Debt0.000.005.580.000.000.00
Issuance of Long Term Debt0.000.005.580.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.450.015.430.000.000.00
Net Change in Cash-0.84-1.433.07-1.15-0.83-1.06
Free Cash Flow-2.29-1.43-2.37-1.15-0.83-1.06

Revenue breakdown

Pharmaceutical Preparations2025: 21.80K
United States2025: 21.80K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.76%0.0M0.9M891.78K
2026-10-154.24%0.0M0.9M970.38K
2026-09-304.03%0.0M0.9M969.05K
2026-09-155.15%0.1M1.0M984.33K
2026-08-317.58%0.1M0.8M968.50K
2026-08-146.06%0.0M0.5M197.39K
2026-07-31-0.0M-183.72K
2026-07-150.79%0.0M0.4M96.29K
2026-06-303.83%0.0M0.3M92.53K
2026-06-150.77%0.0M0.3M79.93K
2026-05-293.16%0.0M0.3M75.72K
2026-05-150.53%0.0M0.2M1.60K
2026-04-300.44%0.0M0.2M1.68K
2026-04-150.49%0.0M0.2M4.30K
2026-03-310.82%0.0M0.2M4.28K
2026-03-130.54%0.0M0.2M4.15K
2026-02-271.47%0.0M0.2M3.65K
2026-02-131.62%0.0M0.2M3.64K
2026-01-303.80%0.0M0.2M3.67K
2026-01-150.14%0.0M0.2M1.32K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-26SCHEDULE 13G/ASEC
2026-10-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-22SCHEDULE 13GSEC
2026-09-04DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-038-KCurrent report2026-08-28SEC
2026-08-28SCHEDULE 13G/ASEC
2026-08-28SCHEDULE 13GSEC
2026-08-288-KCurrent report2026-08-27SEC
2026-08-278-KCurrent report2026-08-26SEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-248-KCurrent report2026-08-21SEC
2026-08-24424B5SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-29424B3SEC
2026-07-288-KCurrent report2026-07-28SEC
2026-07-27424B3SEC
2026-07-278-KCurrent report2026-07-22SEC
2026-07-223Initial statement of beneficial ownership of securities2026-07-22SEC
2026-07-21424B3SEC
2026-07-218-KCurrent report2026-07-20SEC
2026-07-134Statement of changes in beneficial ownership of securities2025-06-02SEC
2026-07-134Statement of changes in beneficial ownership of securities2025-06-02SEC
2026-07-134Statement of changes in beneficial ownership of securities2025-06-02SEC
2026-07-134Statement of changes in beneficial ownership of securities2025-06-02SEC
2026-07-134Statement of changes in beneficial ownership of securities2025-06-02SEC
2026-07-07EFFECTEffectiveness filing by commission orderSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.11%
VESTOR CAPITAL, LLC1.06%
UBS Group AG0.89%
Virtu Financial LLC0.48%
GEODE CAPITAL MANAGEMENT, LLC0.32%
VANGUARD CAPITAL MANAGEMENT LLC0.27%
VANGUARD FIDUCIARY TRUST CO0.17%
XTX Topco Ltd0.07%
Tower Research Capital LLC0.06%
NORTHERN TRUST CORP0.05%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.27%
Fidelity Extended Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.04%
Fidelity Series Total Market Index Fund0.02%
Fidelity Total Market Index Fund0.02%

OakChart. JUNS. Cached 15 minutes.

Some panels did not load: ratings, insider.